{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:28:17Z","timestamp":1791516497041,"version":"4.3.4"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-024-02430-5","type":"journal-article","created":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T05:01:50Z","timestamp":1720501310000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Utilization of neoadjuvant chemotherapy for muscle-invasive bladder cancer in elderly patients: a retrospective cohort study"],"prefix":"10.1007","volume":"41","author":[{"given":"Wesley H.","family":"Chou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solange","family":"Bassale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emile","family":"Latour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhir","family":"Isharwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,9]]},"reference":[{"key":"2430_CR1","unstructured":"Common cancer sites\u2013cancer stat facts. SEER. [Online]. https:\/\/seer.cancer.gov\/statfacts\/html\/common.html. Accessed 24 Mar 2024."},{"issue":"3","key":"2430_CR2","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.eururo.2003.09.019","volume":"45","author":"A Sherif","year":"2004","unstructured":"Sherif A, et al. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur Urol. 2004;45(3):297\u2013303. https:\/\/doi.org\/10.1016\/j.eururo.2003.09.019.","journal-title":"Eur Urol"},{"issue":"9","key":"2430_CR3","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1056\/NEJMoa022148","volume":"349","author":"HB Grossman","year":"2003","unstructured":"Grossman HB, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859\u201366. https:\/\/doi.org\/10.1056\/NEJMoa022148.","journal-title":"N Engl J Med"},{"issue":"1","key":"2430_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7\u201334. https:\/\/doi.org\/10.3322\/caac.21551.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2430_CR5","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.eururo.2014.01.009","volume":"67","author":"ZD Reardon","year":"2015","unstructured":"Reardon ZD, et al. Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides. Eur Urol. 2015;67(1):165\u201370. https:\/\/doi.org\/10.1016\/j.eururo.2014.01.009.","journal-title":"Eur Urol"},{"issue":"3","key":"2430_CR6","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/cncr.22031","volume":"107","author":"A Dash","year":"2006","unstructured":"Dash A, et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer. 2006;107(3):506\u201313. https:\/\/doi.org\/10.1002\/cncr.22031.","journal-title":"Cancer"},{"issue":"3","key":"2430_CR7","doi-asserted-by":"publisher","first-page":"89.e13","DOI":"10.1016\/j.urolonc.2017.11.015","volume":"36","author":"CM Booth","year":"2018","unstructured":"Booth CM, Karim S, Brennan K, Siemens DR, Peng Y, Mackillop WJ. Perioperative chemotherapy for bladder cancer in the general population: are practice patterns finally changing? Urol Oncol. 2018;36(3):89.e13-89.e20. https:\/\/doi.org\/10.1016\/j.urolonc.2017.11.015.","journal-title":"Urol Oncol"},{"issue":"2","key":"2430_CR8","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/UPJ.0000000000000200","volume":"8","author":"JJ Andino","year":"2021","unstructured":"Andino JJ, et al. Understanding the barriers to neoadjuvant chemotherapy in patients with muscle invasive bladder cancer: a quality improvement initiative. Urol Pract. 2021;8(2):217\u201325. https:\/\/doi.org\/10.1097\/UPJ.0000000000000200.","journal-title":"Urol Pract"},{"issue":"3","key":"2430_CR9","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S1470-2045(10)70275-8","volume":"12","author":"MD Galsky","year":"2011","unstructured":"Galsky MD, et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol. 2011;12(3):211\u20134. https:\/\/doi.org\/10.1016\/S1470-2045(10)70275-8.","journal-title":"Lancet Oncol"},{"issue":"2","key":"2430_CR10","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41585-020-00404-6","volume":"18","author":"DM Jiang","year":"2021","unstructured":"Jiang DM, et al. Defining cisplatin eligibility in patients with muscle-invasive bladder cancer. Nat Rev Urol. 2021;18(2):104\u201314. https:\/\/doi.org\/10.1038\/s41585-020-00404-6.","journal-title":"Nat Rev Urol"},{"issue":"6","key":"2430_CR11","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","volume":"24","author":"AR Zlotta","year":"2023","unstructured":"Zlotta AR, et al. Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis. Lancet Oncol. 2023;24(6):669\u201381. https:\/\/doi.org\/10.1016\/S1470-2045(23)00170-5.","journal-title":"Lancet Oncol"},{"issue":"4","key":"2430_CR12","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.urolonc.2013.11.003","volume":"32","author":"FM Patafio","year":"2014","unstructured":"Patafio FM, Mackillop WJ, Feldman-Stewart D, Siemens DR, Booth CM. Why is perioperative chemotherapy for bladder cancer underutilized? Urol Oncol. 2014;32(4):391\u20135. https:\/\/doi.org\/10.1016\/j.urolonc.2013.11.003.","journal-title":"Urol Oncol"},{"issue":"6","key":"2430_CR13","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/j.urology.2013.07.055","volume":"82","author":"S Rehman","year":"2013","unstructured":"Rehman S, et al. Understanding avoidance, refusal, and abandonment of chemotherapy before and after cystectomy for bladder cancer. Urology. 2013;82(6):1370\u20135. https:\/\/doi.org\/10.1016\/j.urology.2013.07.055.","journal-title":"Urology"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-024-02430-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-024-02430-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-024-02430-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T14:14:55Z","timestamp":1722608095000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-024-02430-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,9]]},"references-count":13,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["2430"],"URL":"https:\/\/doi.org\/10.1007\/s12032-024-02430-5","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,9]]},"assertion":[{"value":"4 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"197"}}